IntelliProve Convinced a Belgian Nursing Giant to Back Its Camera-Only Vitals

The Belgian startup's software, which reads heart rate and blood pressure from a facial video, has secured Class IIa medical device status in the EU and is expanding to robots.

About IntelliProve

Published

For clinicians managing chronic conditions like hypertension or heart failure, the gold standard for remote monitoring has long involved a patient dutifully strapping on a cuff or a chest strap. IntelliProve, a startup from Ghent, Belgium, is betting that future can be frictionless, powered by nothing more than the camera already in a patient's smartphone, tablet, or, soon, a humanoid robot [The Next Web, November 2026]. Its core technology is a software layer that analyzes a 30-second video of a person's face to estimate vital signs like heart rate, heart rate variability, breathing rate, and blood pressure, all without physical contact [IntelliProve, Technology: inside our health sensing layer]. The ambition is not to replace clinical-grade equipment in a hospital, but to weave passive, objective health sensing into the digital workflows where patients already are.

What makes the company's recent progress noteworthy is not just the underlying computer vision, but its deliberate march through the regulatory gauntlet. While many wellness apps measure similar signals, IntelliProve has secured a CE mark as a Class IIa medical device under the European Union's Medical Device Regulation [Robotics 24/7, Unknown]. This classification, which the company is actively pursuing according to public statements, signifies a higher bar for clinical validation and risk management. It is a necessary credential for the software to be integrated into reimbursable care pathways and used by healthcare professionals for decision support, moving it beyond the realm of consumer wellness.

The clinical wedge

The company's wedge is access. By turning any device with a camera into a potential health sensor, IntelliProve allows digital health companies, telehealth providers, and insurers to embed remote physiological monitoring into their existing applications without asking users to buy or wear additional hardware [Startup Centrum, November 2026]. The technology is already integrated into partner platforms that operate in more than 50 countries, according to the company [The Next Web, November 2026]. These include named partners like the wellbeing platforms BloomUp and OptimallyMe, and the Belgian health insurer Neutraal Ziekenfonds Vlaanderen.

For a patient population managing cardiovascular risk or stress-related conditions, the promise is a less intrusive form of longitudinal tracking. Instead of sporadic readings from a device they must remember to use, their vitals could be passively checked during a routine video check-in with a nurse or a mental health coach. IntelliProve positions its facial analysis as a source of objective biomarkers for mental health, suggesting use cases where stress and autonomic nervous system activity are clinically relevant [IntelliProve, Docs overview].

Funding a regulated expansion

The company, founded in 2021, has raised a total of approximately $2.33 million across three seed rounds to fund this regulated build-out [Tracxn, Unknown]. Its most recent announced financing was a €2.7 million round in November 2026, led by existing investor Miles Ahead and joined by a strategic backer: Wit-Gele Kruis, a major Belgian home-nursing organization [The Next Web, November 2026]. The participation of a care provider is a tangible vote of confidence in the technology's clinical utility and pathway to adoption.

Date Amount Lead Investor Key Participants / Notes
November 2022 €1 million Not specified First announced seed round [Tech Funding News, November 2026]
January 2025 €1.25 million Miles Ahead Second seed round [Tech Funding News, November 2026]
November 2026 €2.7 million Miles Ahead Wit-Gele Kruis, imec.istart Fund, business angels [The Next Web, November 2026]

The founding team brings together pharmaceutical science and technical depth. Co-CEO Joeri Tulkens holds a PhD in Pharmaceutical Sciences from Ghent University, providing a foundation in clinical research and biomarker validation [Joeri Tulkens, PhD - IntelliProve | LinkedIn, retrieved 2026]. He shares leadership with co-founder Maxime Mattelin, while Brecht Dhuyvetters serves as chief product officer and Tanguy Sanglet as chief technology officer [IntelliProve, Company].

The path beyond the smartphone

With the core software established and regulatory work underway, IntelliProve is exploring new hardware frontiers. The company has stated it is adapting its "health sensing layer" for integration into humanoid robots and other connected devices with cameras [Robotics 24/7, Unknown]. This aligns with a broader industry trend of adding ambient, context-aware sensing to robotic assistants, particularly in elder care settings where continuous, unobtrusive monitoring could be valuable.

The company also emphasizes its enterprise-grade security posture, with an ISO 27001 certification for its Information Security Management System, a critical consideration for handling sensitive health data [IntelliProve, Security].

The validation hurdle

For all its regulatory progress and geographic reach, IntelliProve's long-term success hinges on the clinical robustness of its measurements, especially for blood pressure. Photoplethysmography (PPG) through a camera to estimate heart rate is a well-established technique, but deriving accurate, calibrated blood pressure readings from facial video signals remains a significant technical and clinical challenge. The company's claims are backed by over nine years of academic and clinical research, it states [IntelliProve, Research]. Yet, the ultimate test will be the publication of peer-reviewed studies demonstrating the accuracy and reproducibility of its estimates across diverse populations and real-world conditions.

The competitive landscape is another factor. While no direct competitors are named in the available sources, the field of camera-based health sensing is attracting attention from large tech companies and specialized startups alike. IntelliProve's early focus on the regulated medical device path and its partnerships with European care providers could provide a defensible moat.

  • Regulatory head start. The pursuit of a Class IIa CE mark places it ahead of many consumer-facing apps in terms of credibility with healthcare providers.
  • Strategic alignment. An investor like Wit-Gele Kruis is not just capital; it's a potential launch customer and source of clinical feedback within the Belgian healthcare system.
  • Integration breadth. Being deployed on platforms from smartphones to kiosks to robots gives the technology multiple routes to patient touchpoints.

For patients with hypertension or heart failure, the current standard of care for remote monitoring often involves a Bluetooth-enabled blood pressure cuff. It provides accurate readings but depends on patient adherence and adds another device to their life. IntelliProve's vision is to make the measurement disappear into the background of a digital interaction. The next twelve months will be critical for the company to translate its European regulatory milestone into published clinical data and scaled deployments with its care-provider partners. If the software performs as promised under rigorous scrutiny, it could meaningfully lower the barrier to frequent, passive vital sign monitoring for millions of patients.

Sources

  1. [The Next Web, November 2026] IntelliProve raises €2.7M to take its face scan health check to robots | https://thenextweb.com/news/intelliprove-2-7m-seed-face-scan-humanoid-robots
  2. [IntelliProve, Technology: inside our health sensing layer] IntelliProve Technology | https://intelliprove.com/
  3. [Robotics 24/7, Unknown] IntelliProve is taking its technology further by CE marking as a Class IIa medical device | Not available
  4. [Startup Centrum, November 2026] IntelliProve raises €2.7M | https://media.startupcentrum.com/en/intelliprove-raises-e2-7m/
  5. [Tracxn, Unknown] IntelliProve - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/intelliprove
  6. [Tech Funding News, November 2026] IntelliProve raises €2.7M from Miles Ahead to turn any camera into a health sensor | https://techfundingnews.com/intelliprove-raises-e2-7m-from-miles-ahead-to-turn-any-camera-into-a-health-sensor/
  7. [Joeri Tulkens, PhD - IntelliProve | LinkedIn, retrieved 2026] Joeri Tulkens LinkedIn Profile | https://www.linkedin.com/in/joeritulkens/
  8. [IntelliProve, Company] IntelliProve Company Page | https://intelliprove.com/company
  9. [IntelliProve, Docs overview] IntelliProve Documentation | https://intelliprove.com/
  10. [IntelliProve, Research] IntelliProve Research | https://intelliprove.com/
  11. [IntelliProve, Security] IntelliProve Security | https://intelliprove.com/

Read on Startuply.vc